About Beta Drugs
Beta Drugs is a company based in Panchkula (India) founded in 2005. The company has 382 employees. Beta Drugs offers products and services including Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing. Beta Drugs operates in a competitive market with competitors including Jazz Pharmaceuticals, Pharmaron, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Panchkula, India
- Employees 382
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website betadrugslimited.com
- Social LinkedIn
- Legal Name Beta Drugs Ltd.
- Annual Revenue₹369 Cr
FY 2025 · +24% YoY
- Net Profit₹42.42 Cr
FY 2025 · 12% margin
- EBITDA₹76.47 Cr
FY 2025 · 21% margin
- Latest Funding Round$13.88 M (USD), Post-IPO
Nov 27, 2024
- Investors
- Employee Count382
Associated legal entities of Beta Drugs
Beta Drugs is associated with 2 registered companies on The Company Check; the primary company is Beta Drugs Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Beta Drugs Limited Listed CIN L24230HP2005PLC028969 | Active | 21 Sep 2005 | Baddi, Himachal Pradesh | ₹369 Cr | 382 | 12 | View details |
| Adley Formulations Private Limited CIN U24303HR2018PTC076347 | Active | 09 Oct 2018 | Panchkula, Haryana | ₹85.9 Cr | 193 | 5 | View details |
Products & Services of Beta Drugs
Beta Drugs offers a comprehensive portfolio of products and services, including Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing.
Medications for cancer treatment and patient care.
Solutions for skin health and dermatological issues.
Innovation in active pharmaceutical ingredients processes.
Production services for other pharmaceutical companies.
Funding Insights of Beta Drugs
- Total Rounds 1
- Last Round Post-IPO — $13.9M
- First Round $13.9M
(27 Nov 2024)
- Investors Count 1
All 1 funding rounds of Beta Drugs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 27 Nov 2024 | $13.9M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Beta Drugs
Beta Drugs has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include HealthQuad.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investment fund focused on innovation and social impact in India. | 2016 | healthquad.in | Delhi, India |
Investor details for Beta Drugs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Beta Drugs Limited (Beta Drugs)
Beta Drugs Limited is the primary company behind Beta Drugs. The boards of the 2 registered companies of Beta Drugs currently have 11 directors; the longest-serving is Balwant Singh, appointed in 2014. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Balwant Singh DIN 01089968 | Whole-time director | 01 Aug 2014 | 12 yrs 2 mo | Beta Drugs Limited |
| Varun Batra DIN 02148383 | Managing Director | 01 Aug 2014 | 12 yrs 2 mo | Beta Drugs Limited, Adley Formulations Private Limited |
| Rahul Batra DIN 02229234 | Managing Director | 01 Aug 2014 | 12 yrs 2 mo | Beta Drugs Limited, Adley Formulations Private Limited |
| Rohit Parti DIN 07889944 | Director | 26 Jul 2017 | 9 yrs 2 mo | Beta Drugs Limited |
| Manmohan Khanna DIN 07888319 | Director | 26 Jul 2017 | 9 yrs 2 mo | Beta Drugs Limited |
| Ram Chandra Jha DIN 08253187 | Whole-time director | 09 Oct 2018 | 8 yrs | Adley Formulations Private Limited |
| Ashutosh Shukla DIN 09461568 | Whole-time director | 20 Jan 2022 | 4 yrs 8 mo | Beta Drugs Limited |
| Sanjay Sehgal DIN 01235531 | Director | 27 Nov 2024 | 1 yr 10 mo | Beta Drugs Limited |
| Ajay Mahipal DIN 06949940 | Director | 27 Nov 2024 | 1 yr 10 mo | Beta Drugs Limited |
| Monica Jain DIN 05253864 | Director | 05 Feb 2025 | 1 yr 8 mo | Beta Drugs Limited, Adley Formulations Private Limited |
| Lalit Kumar Watts DIN 10906518 | Director | 05 Feb 2025 | 1 yr 8 mo | Beta Drugs Limited |
People of Beta Drugs
1 people are tracked at Beta Drugs (1 in leadership); the tracked headcount is 382.
| Name | Role | Group |
|---|---|---|
| Chairman & Managing Director | Leadership |
Complete people profiles for Beta Drugs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Beta Drugs
Beta Drugs is a publicly listed company on the NSE with ticker symbol BETA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Oct 2017
- Listed onNSE: BETA
- Listed entityBeta Drugs Ltd.
- Exchange sectorHealth technology
- ISININE351Y01019
- Share price₹1,733.00 (-8.69% on the day) · 2026-10-09
- Market capitalisation₹2,104 Cr
- Price to earnings39.2
- EPS (diluted, trailing year)₹44.21
- Volume (last session)100,343
Financials of Beta Drugs
Figures of Beta Drugs Limited, the primary company behind Beta Drugs, for FY 2025. Revenue was ₹369 Cr (+24% year on year). Net profit was ₹42.42 Cr (12% margin). EBITDA was ₹76.47 Cr (21% margin). Revenue has grown at a compounded annual rate of +26% over three years and +32% over five years.
- ₹369 CrRevenue · FY 2025 · +24% YoY
- ₹42.42 CrNet profit · 12% margin
- ₹76.47 CrEBITDA · 21% margin
- ₹10.14 CrPaid-up capital
- 382Employees (provident fund records)
- +26%Revenue CAGR, 3 years
- +32%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | ₹384 Cr | ₹41.5 Cr | ₹76.9 Cr |
| 2024 | ₹362 Cr | ₹42.4 Cr | ₹75.7 Cr |
| 2023 | ₹295 Cr | ₹36.4 Cr | ₹60.0 Cr |
| 2022 | ₹227 Cr | ₹30.7 Cr | ₹54.0 Cr |
| 2021 | ₹184 Cr | ₹24.8 Cr | ₹42.9 Cr |
Balance sheet, profit and loss, cash flow and ratios of Beta Drugs Limited are on its company page.
Detailed financial statements for Beta Drugs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Beta Drugs
3 dated milestones of Beta Drugs across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Beta Drugs is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $13.9M.
Competitors of Beta Drugs
Beta Drugs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Pharmaron, Revolution Medicines, Blueprint Medicines and Syndax, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265.0M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| pharmaron.com | 2003 | Beijing, China | $320.0M | 476 | Drug discovery and development services for small molecules are provided. | |
| revmed.com | 2014 | Redwood, United States | $326.3M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115.0M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.3M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223.0M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300.0M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119.0M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.5M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Beta Drugs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beta Drugs
Complete news archive for Beta Drugs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Beta Drugs
10 companies that operate in the same segment as Beta Drugs (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Beta Drugs
Beta Drugs was founded in 2005 and raised its 1st funding round 19 years after it was founded.
Beta Drugs is headquartered in Panchkula, India. It is registered at Panchkula, Haryana, India.
Beta Drugs has 382 employees.
The primary company behind Beta Drugs, Beta Drugs Limited, reported revenue of ₹369 Cr for FY 2025, up 24% year on year.
Beta Drugs was founded in 2005 and is based in Panchkula, India. Therapeutics targeting oncology and dermatology are developed within the pharmaceutical sector. Specific products, including nanoparticle-albumin-bound paclitaxel, docetaxel, and gemcitabine, are offered as tablets, capsules, oral liquids, and injectables. Additional services encompass method development, qualification, validation, transfer, stability protocol creation, pre-formulation studies, and related activities.
Beta Drugs's top competitors include Jazz Pharmaceuticals, Pharmaron and C4 Therapeutics.
Beta Drugs offers Oncology Products, Cosmeceutical Products, API Development, and Contract Manufacturing.
Yes, Beta Drugs is publicly traded on NSE under the ticker symbol BETA.
Beta Drugs has 1 investor. Key investors include HealthQuad.
Beta Drugs is associated with 2 legal entities: Beta Drugs Limited, Adley Formulations Private Limited.
The legal entities of Beta Drugs currently have 13 directors, including Balwant Singh, Rohit Parti, Manmohan Khanna and others.